Clinical trial
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent…
NCT00082758 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00082758 |
|---|---|
| Title | hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma |
| Official title | A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | hu14.18-Interleukin-2 fusion protein |
| Enrollment | 39 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | May 1, 2012 |
| First posted | May 19, 2004 |
| Last update posted | Feb 12, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: